Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 nitazoxanide studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Exclusions   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Cases   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 36% 12 3,530 Improvement, Studies, Patients Relative Risk Mortality 42% 6 1,877 Ventilation 82% 3 588 ICU admission 28% 3 841 Hospitalization 61% 6 1,864 Recovery 5% 4 1,233 Cases 17% 1 505 Viral clearance 52% 6 790 RCTs 9% 9 2,879 RCT mortality 28% 4 1,339 Peer-reviewed 58% 9 2,532 Prophylaxis 66% 1 505 Early 33% 7 2,469 Late 12% 4 556 Nitazoxanide for COVID-19 c19nitazoxanide.com Aug 2022 Favorsnitazoxanide Favorscontrol after exclusions
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION RECOVERY CASES VIRAL CLEARANCE RANDOMIZED CONTROLLED TRIALS RCT MORTALITY PEER-REVIEWED After Exclusions ALL STUDIES All Prophylaxis Early Late Nitazoxanide for COVID-19 C19NITAZOXANIDE.COM AUG 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Tau​2​ = 1.12, I​2​ = 80.8%, p = 0.43 Early treatment 33% 0.67 [0.25-1.78] 25/1,359 51/1,110 33% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 7.9%, p = 0.65 Late treatment 12% 0.88 [0.52-1.50] 9/275 16/281 12% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 36% 0.64 [0.34-1.22] 34/1,874 68/1,656 36% improvement 12 nitazoxanide COVID-19 studies c19nitazoxanide.com Aug 2022 Tau​2​ = 0.70, I​2​ = 71.6%, p = 0.18 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Tau​2​ = 0.71, I​2​ = 72.1%, p = 0.091 Early treatment 55% 0.45 [0.18-1.14] 10/897 46/667 55% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 7.9%, p = 0.65 Late treatment 12% 0.88 [0.52-1.50] 9/275 16/281 12% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 47% 0.53 [0.29-0.99] 19/1,412 63/1,213 47% improvement 11 nitazoxanide COVID-19 studies after exclusions c19nitazoxanide.com Aug 2022 Tau​2​ = 0.53, I​2​ = 65.4%, p = 0.044 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 88% 0.12 [0.01-2.52] 0/357 2/137 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Tau​2​ = 2.67, I​2​ = 51.4%, p = 0.75 Early treatment 41% 0.59 [0.02-13.8] 1/541 2/332 41% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 42% 0.58 [0.27-1.24] 10/1,025 19/852 42% improvement 6 nitazoxanide COVID-19 mortality results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 97% 0.03 [0.00-0.51] 0/357 9/137 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Early treatment 97% 0.03 [0.00-0.51] 0/357 9/137 97% improvement Blum (DB RCT) 62% 0.38 [0.11-1.25] 3/25 8/25 Improvement, RR [CI] Treatment Control Calderón 87% 0.13 [0.01-2.33] 0/17 4/27 OT​1​ Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.044 Late treatment 68% 0.32 [0.11-0.97] 3/42 12/52 68% improvement All studies 82% 0.18 [0.04-0.76] 3/399 21/189 82% improvement 3 nitazoxanide COVID-19 mechanical ventilation results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.50, I​2​ = 27.5%, p = 0.019 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] 2/194 0/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment -404% 5.04 [0.24-104] 2/194 0/198 -404% improvement Calderón 59% 0.41 [0.25-0.59] 0/17 16/27 OT​1​ Improvement, RR [CI] Treatment Control Rocco (DB RCT) 31% 0.69 [0.40-1.17] 20/202 30/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.15 Late treatment 32% 0.68 [0.40-1.15] 20/219 46/230 32% improvement All studies 28% 0.72 [0.43-1.21] 22/413 46/428 28% improvement 3 nitazoxanide COVID-19 ICU results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Improvement, RR [CI] Treatment Control Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Tau​2​ = 3.68, I​2​ = 78.4%, p = 0.16 Early treatment 83% 0.17 [0.01-2.00] 6/735 37/530 83% improvement Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Improvement, RR [CI] Treatment Control Calderón 52% 0.48 [0.29-0.82] hosp. time 17 (n) 27 (n) OT​1​ Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0004 Late treatment 53% 0.47 [0.31-0.71] 0/42 0/52 53% improvement Sokhela (RCT) 79% 0.21 [0.01-4.31] hosp. 0/240 2/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.31 Prophylaxis 79% 0.21 [0.01-4.31] 0/240 2/265 79% improvement All studies 61% 0.39 [0.20-0.78] 6/1,017 39/847 61% improvement 6 nitazoxanide COVID-19 hospitalization results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.29, I​2​ = 47.9%, p = 0.0078 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Tau​2​ = 0.54, I​2​ = 26.7%, p = 0.32 Early treatment -95% 1.95 [0.53-7.22] 18/1,197 7/973 -95% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 8% 0.92 [0.39-2.16] 27/1,681 24/1,493 8% improvement 8 nitazoxanide COVID-19 serious outcomes c19nitazoxanide.com Aug 2022 Tau​2​ = 0.51, I​2​ = 37.8%, p = 0.86 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -7% 1.07 [0.46-2.49] recov. time 184 (n) 195 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.37 Early treatment -15% 1.15 [0.85-1.54] 59/378 52/393 -15% improvement Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​1​ Improvement, RR [CI] Treatment Control Rocco (DB RCT) 27% 0.73 [0.58-0.90] no disch. 202 (n) 203 (n) Tau​2​ = 0.04, I​2​ = 45.6%, p = 0.33 Late treatment 17% 0.83 [0.57-1.21] 0/233 0/229 17% improvement All studies 5% 0.95 [0.70-1.28] 59/611 52/622 5% improvement 4 nitazoxanide COVID-19 recovery results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.05, I​2​ = 54.8%, p = 0.75 ​1​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Sokhela (RCT) 17% 0.83 [0.50-1.40] symp. case 23/240 37/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.47 Prophylaxis 17% 0.83 [0.50-1.40] 23/240 37/265 17% improvement All studies 17% 0.83 [0.51-1.36] 23/240 37/265 17% improvement 1 nitazoxanide COVID-19 case result c19nitazoxanide.com Aug 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.47 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Improvement, RR [CI] Treatment Control Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Tau​2​ = 0.58, I​2​ = 90.3%, p = 0.055 Early treatment 54% 0.46 [0.21-1.02] 7/356 44/335 54% improvement Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 Improvement, RR [CI] Treatment Control Fowotade (RCT) 5% 0.95 [0.34-2.64] viral load 31 (n) 26 (n) CT​1​ Tau​2​ = 1.31, I​2​ = 52.6%, p = 0.48 Late treatment 53% 0.47 [0.06-3.59] 0/54 4/45 53% improvement All studies 52% 0.48 [0.25-0.94] 7/410 48/380 52% improvement 6 nitazoxanide COVID-19 viral clearance results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.49, I​2​ = 84.9%, p = 0.032 ​1​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Tau​2​ = 0.50, I​2​ = 64.3%, p = 0.84 Early treatment -10% 1.10 [0.47-2.59] 18/940 5/922 -10% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 8.5%, p = 0.86 Late treatment 5% 0.95 [0.55-1.63] 8/258 11/254 5% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 9% 0.91 [0.56-1.48] 26/1,438 17/1,441 9% improvement 9 nitazoxanide COVID-19 Randomized Controlled Trials c19nitazoxanide.com Aug 2022 Tau​2​ = 0.20, I​2​ = 42.8%, p = 0.72 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Early treatment -206% 3.06 [0.13-74.6] 1/184 0/195 -206% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Rocco (DB RCT) -5% 1.05 [0.30-3.50] 6/202 5/203 Tau​2​ = 0.19, I​2​ = 28.2%, p = 0.46 Late treatment 35% 0.65 [0.22-1.98] 8/227 11/228 35% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 28% 0.72 [0.31-1.70] 9/651 12/688 28% improvement 4 nitazoxanide COVID-19 RCT mortality results c19nitazoxanide.com Aug 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Tau​2​ = 0.84, I​2​ = 67.1%, p = 0.11 Early treatment 61% 0.39 [0.13-1.23] 10/874 46/654 61% improvement Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% improvement Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% improvement All studies 58% 0.42 [0.20-0.86] 19/1,358 63/1,174 58% improvement 9 nitazoxanide COVID-19 peer reviewed trials c19nitazoxanide.com Aug 2022 Tau​2​ = 0.50, I​2​ = 51.4%, p = 0.018 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Rocco (RCT) 14% 0.86 [0.77-0.96] viral+ 136/194 162/198 Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Cadegiani 97% 0.03 [0.00-0.51] ventilation 0/357 9/137 Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Elalfy 58% 0.42 [0.31-0.56] viral+ 26/62 51/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Silva (SB RCT) 38% 0.62 [0.39-0.97] viral+ 12/23 11/13 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Rossignol (DB RCT) 85% 0.15 [0.02-1.22] severe case 1/184 7/195 Rossignol (DB RCT) 84% 0.16 [0.02-1.29] severe case 1/112 7/126 Rossignol (DB RCT) -7% 1.07 [0.46-2.49] recov. time 184 (n) 195 (n) ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Blum (DB RCT) 62% 0.38 [0.11-1.25] ventilation 3/25 8/25 Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Blum (DB RCT) 90% 0.10 [0.01-1.78] viral+ 0/23 4/19 Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Calderón 87% 0.13 [0.01-2.33] ventilation 0/17 4/27 OT​1​ Calderón 59% 0.41 [0.25-0.59] ICU 0/17 16/27 OT​1​ Calderón 52% 0.48 [0.29-0.82] hosp. time 17 (n) 27 (n) OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Fowotade (RCT) -87% 1.87 [0.88-3.98] no recov. 31 (n) 26 (n) CT​2​ Fowotade (RCT) 5% 0.95 [0.34-2.64] viral load 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Rocco (DB RCT) <